Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after announcing positive long-term clinical data for its CelGro® nerve repair study. The regenerative medicine company has decided that the clinical results have met the study objectives and has now closed recruitment. They're progressing regulatory applications in Australia and will start the US regulatory study shortly.
Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study
Quick facts: Orthocell Ltd
Price: 0.535 AUD
Market Cap: $99.18 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE